Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2013-02-14 | recombinant adeno-associated viral vector containing the human retinoschisin gene | TMC Pharma Services Ltd (UK) | X-linked juvenile retinoschisis | |
2013-02-14 | 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one | Janssen-Cilag International - J&J (USA) | mantle cell lymphoma | |
2013-02-14 | 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid | Sanofi (France) | systemic sclerosis |
Granting of the orphan status in the EU |
2017-06-28 | mepolizumab | GSK (UK) | eosinophilic granulomatosis with polyangiitis (EGPA) previously known as Churg-Strauss syndrome | Submission of a Market Application in the US |
2013-02-14 | ramiprilat | Iris Pharma (France) | Stargardt’s disease | |
2013-02-18 | everolimus | Novartis (Switzerland) | prophylaxis of organ rejection in adult patients receiving a liver transplant |
Granting of a Market Authorisation in the US |
2013-02-21 | certolizumab pegol | UCB (Belgium) | active psoriatic arthritis (PsA) |
Granting of a Market Authorisation in the EU |
2013-02-21 | certolizumab pegol | UCB (Belgium) | active axial spondyloarthritis (axSpA) |
Granting of a Market Authorisation in the US |
2013-02-21 | smilagenin | Phytopharm (UK) | amyotrophic lateral sclerosis |
Granting of the orphan status in the EU |
2013-02-21 | remestemcel-L | Osiris Therapeutics (USA - MD) | acute graft-versus-host disease (GvHD) |
Granting of the orphan status in the EU |
2013-02-21 | allergen immunotherapy sublingual tablet consisting of five purified and calibrated pollen extracts | Stallergenes (France) | allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens | |
2015-09-22 | PledPharma (Sweden) | cancer |
Granting of a patent | |
2013-02-21 | human growth hormone | Prolor Biotech (Israel) | Granting of the orphan status in the EU | |
2013-02-24 | diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) | Sanofi (France) | Primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type B (Hib).
|
|
2013-02-24 | simeprevir (TMC435) | Janssen (J&J - USA) | genotype 1 and 4 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis |
Granting of a patent |
2013-02-28 | enzyme-based reagent | Cytori Therapeutics (USA) | intravascular delivery | |
2013-03-01 | cultured autologous chondrocytes on hyaluronan based scaffold | Anika Therapeutics (Italy) | surgical repair of symptomatic cartilage defects of the femoral condyle (medial, lateral) or trochlea, caused by acute or repetitive trauma in adults | |
2013-03-06 | Roche (Switzerland) | hepatitis C | ||
2013-03-06 | Dako (Denmark), an Agilent Technologies company (USA - CA) | HER2-positive metastatic or locally recurrent unresectable breast cancer |
Granting of a Market Authorisation in the US | |
2013-03-06 | Dako (Denmark), an Agilent Technologies company (USA - CA) | HER2-positive metastatic breast cancer |
Granting of a Market Authorisation in the US |
© 2024 Biopharmanalyses - Powered by Samacom+